James Halley

Oracle's data centers need power, and Bloom Energy's fuel cells are delivering it.

Johnson & Johnson and Merck are healthcare giants with dependable returns that weather economic downturns well.

Oklo's stock surged more than 12% on Aug. 25. I'm still staying away.

The companies are not that much alike, but they're both showing strong revenue and earnings growth.

These three industrial stocks are quietly benefiting from the AI boom.

Constellation keeps racking up the deals, but its stock is trading more than 51% below its 52-week high.

Duquesne Family Office has beefed up its healthcare holdings.

Green Thumb Industries is in a strong position to acquire other cannabis companies, but will that happen?

This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.

Waste Management's share growth hasn't kept up with its revenue and EPS growth this year.

Barrick saw attributable adjusted EBITDA and earnings rise in the second quarter.

Ken Griffin sees a bargain in Abbvie and increased his fund's position by buying 2.68 million shares of the healthcare giant.

Enbridge's solid history of dependable dividends has made it a favorite of income-oriented investors.

The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.

Constellation Energy represents a great, stable utility that uses nuclear power, while Cameco Corporation is a North America-based uranium miner that supplies nuclear facilities.

The midstream company raised its guidance for yearly adjusted EBITDA during its second-quarter earnings report.

Barrick Mining's shares are down about 20% from their 52-week high.

Comfort Systems has been twice as good for investors as Nvidia over the past half-decade.

The stock, up more than 7% this year, is down 5% since its second-quarter earnings report.

The pharmaceutical company hopes that another big-time acquisition will pay off.